Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (odpre novo okno)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Vir‎: Br J Haematol 2013;161(5):738-40.

Indeksirano‎: PubMed 23480574

DOI‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (odpre novo okno)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (odpre novo okno)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Vir‎: Haematologica 2021;106(4):1148-57.

Indeksirano‎: PubMed 32499239

DOI‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (odpre novo okno)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (odpre novo okno)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Vir‎: Cancer 2008;113(6):1338-43.

Indeksirano‎: PubMed 18629842

DOI‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (odpre novo okno)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (odpre novo okno)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Vir‎: Transfusion 2012;52(4):739-41.

Indeksirano‎: PubMed 22082044

DOI‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (odpre novo okno)

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (odpre novo okno)

Bhatia M, Davenport V, Cairo MS.

Vir‎: Leuk Lymphoma 2007;48(1):9-15.

Indeksirano‎: PubMed 17325843

DOI‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 (odpre novo okno)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (odpre novo okno)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Vir‎: BMC Cancer 2013;13:121.

Indeksirano‎: PubMed 23497336

DOI‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (odpre novo okno)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (odpre novo okno)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Vir‎: Pathol Oncol Res 2011;17(1):141-3.

Indeksirano‎: PubMed 20628840

DOI‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (odpre novo okno)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (odpre novo okno)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Vir‎: J Neurooncol 2012;106(2):427-9.

Indeksirano‎: PubMed 21833801

DOI‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (odpre novo okno)

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (odpre novo okno)

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

Vir‎: Lancet 2003;361(9354):275-80.

Indeksirano‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 (odpre novo okno)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (odpre novo okno)

Ford PA, Grant SJ, Mick R, Keck G.

Vir‎: J Clin Oncol 2015;33(15):1674-9.

Indeksirano‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (odpre novo okno)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (odpre novo okno)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Vir‎: Platelets. 2022 3;33(7):1024-1030.

Indeksirano‎: PubMed 35040375

DOI‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (odpre novo okno)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (odpre novo okno)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Vir‎: Cancer 2014;120(12):1838-46.

Indeksirano‎: PubMed 24706489

DOI‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (odpre novo okno)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (odpre novo okno)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Vir‎: Leuk Lymphoma 2013;54(2):321-8.

Indeksirano‎: PubMed 22906162

DOI‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (odpre novo okno)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (odpre novo okno)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Vir‎: Platelets 2012;23(6):423-9.

Indeksirano‎: PubMed 22185370

DOI‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (odpre novo okno)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (odpre novo okno)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Vir‎: Ann Hematol 2015;94(1):117-28.

Indeksirano‎: PubMed 25069650

DOI‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (odpre novo okno)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (odpre novo okno)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Vir‎: J Hematol Oncol 2015;8:37.

Indeksirano‎: PubMed 25886818

DOI‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (odpre novo okno)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (odpre novo okno)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Vir‎: J Clin Oncol 2010;28(3):437-44.

Indeksirano‎: PubMed 20008626

DOI‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (odpre novo okno)

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (odpre novo okno)

Locantore-Ford P, Grant SJ, Keck G.

Vir‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 (odpre novo okno)

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (odpre novo okno)

Loo M, Beguin Y.

Vir‎: Blood 1999;93(10):3286-93.

Indeksirano‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 (odpre novo okno)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (odpre novo okno)

Miao J, Leblebjian H, Scullion B, Parnes A

Vir‎: Am J Hematol 2018;93(4):E86-E88.

Indeksirano‎: PubMed 29274130

DOI‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (odpre novo okno)

Pharmacological therapies to minimise platelet transfusion. (odpre novo okno)

Norfolk DR, Seghatchian J.

Vir‎: Transfus Sci 2000;22(3):149-53.

Indeksirano‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 (odpre novo okno)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (odpre novo okno)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Vir‎: Support Care Cancer 2014;22(5):1217-22.

Indeksirano‎: PubMed 24414994

DOI‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (odpre novo okno)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (odpre novo okno)

Pathak S, Roth M, Verma A, Steidl U.

Vir‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

Indeksirano‎: PubMed 24215532

DOI‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (odpre novo okno)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (odpre novo okno)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Vir‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indeksirano‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (odpre novo okno)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (odpre novo okno)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Vir‎: Lancet Haematol 2015;2(10):e417-26.

Indeksirano‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (odpre novo okno)

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (odpre novo okno)

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

Vir‎: Am J Blood Res 2013;3(3):260-4.

Indeksirano‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 (odpre novo okno)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (odpre novo okno)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Vir‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

Indeksirano‎: PubMed 26306064

DOI‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (odpre novo okno)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (odpre novo okno)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Vir‎: Blood 2010;116(12):2127-33.

Indeksirano‎: PubMed 20530792

DOI‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (odpre novo okno)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (odpre novo okno)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Vir‎: Blood 2012;120(2):386-94.

Indeksirano‎: PubMed 22627766

DOI‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (odpre novo okno)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (odpre novo okno)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Vir‎: Cancer 2011;117(5):992-1000.

Indeksirano‎: PubMed 20945323

DOI‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (odpre novo okno)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (odpre novo okno)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Vir‎: J Clin Oncol 2019;37(31):2892-8.

Indeksirano‎: PubMed 31545663

DOI‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (odpre novo okno)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (odpre novo okno)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Vir‎: Blood 2000;95(9):2983-9.

Indeksirano‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (odpre novo okno)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (odpre novo okno)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Vir‎: Eur J Haematol 2014;93(5):439-45.

Indeksirano‎: PubMed 24853277

DOI‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (odpre novo okno)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (odpre novo okno)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Vir‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

Indeksirano‎: PubMed 26785333

DOI‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (odpre novo okno)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (odpre novo okno)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Vir‎: Ann Oncol 2005;16(1):139-45.

Indeksirano‎: PubMed 15598951

DOI‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (odpre novo okno)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (odpre novo okno)

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

Vir‎: J Hematol Oncol 2012;5:71.

Indeksirano‎: PubMed 23190430

DOI‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 (odpre novo okno)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (odpre novo okno)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Vir‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

Indeksirano‎: PubMed 35582038

DOI‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (odpre novo okno)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (odpre novo okno)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Vir‎: Blood 2009;114(18):3899-908.

Indeksirano‎: PubMed 19710504

DOI‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (odpre novo okno)